MA-VERACODE
2.4.2024 09:31:35 CEST | Business Wire | Press release
Veracode, a global leader in application risk management, today announced the acquisition of Longbow Security, a pioneer in security risk management for cloud-native environments. The acquisition marks the next exciting phase of Veracode, underscoring the company’s commitment to help organizations effectively manage and reduce application risk across the growing attack surface.
The integration of Longbow into Veracode enables security teams to discover cloud and application assets quickly and easily assess their threat exposure using automated issue investigation and root cause analysis. Longbow provides a centralized view of risk for cloud assets and applications, thereby simplifying complex workflows, enabling faster and more effective remediation, and improving overall security posture. The result is reduced risk and fewer vulnerabilities in applications and cloud infrastructures.
Increased adoption of cloud infrastructure, combined with developers taking on more responsibility for the creation, deployment, and security of software, has introduced operational complexity. Organizations now require a deeper understanding of their risk profile within changing environments and a continuous security feedback loop throughout the software development life cycle.
“Security teams are drowning in alerts that lack sufficient detail on the level of business risk, degree of exploitability of a flaw, and specific code-level insight to keep pace with remediation requirements. As a result, risk continues to accumulate,” said Brian Roche, Chief Product Officer at Veracode. “With the combination of Veracode and Longbow, teams can get a comprehensive view of their risk, automate prioritization of what matters most, and, with Veracode Fix, automate remediation of code security flaws.”
Longbow and Veracode Simplify Cloud Application Security for Overloaded Teams
With 71 percent of organizations shouldering the burden of “security debt” (flaws in applications that remain unfixed for one year), teams must act quickly to reduce their threat exposure. Yet, sufficient visibility and alert fatigue continue to plague cloud and application security professionals today. With Longbow, Veracode customers can address these challenges in four ways:
- Unified visibility of risk across applications, code, and cloud. This gives teams insight to tackle significant issues that matter most to the business.
- Orchestrated remediation from code to cloud, enabling teams to prioritize and remediate with Veracode’s AI-driven fix capabilities.
- Actionable insights with ‘Best Next Action’ advice, so customers can conduct a root cause analysis and pinpoint the best path to remediation.
- Continuous monitoring and assessment via real-time vulnerability discovery across application portfolios and runtime environments, meaning customers know exactly what is running and where.
Derek Maki, Co-Founder & Chief Product Officer at Longbow said, “We founded Longbow with a mission to simplify an increasingly complex application security risk management process and help organizations reduce risk at scale. By joining forces with Veracode, our combined solutions provide unmatched visibility, automation, and remediation capability for security and engineering teams. We are excited to take cloud-native application security to the next level.”
“This is the perfect fit for Longbow,” said Dayne Myers, Co-founder & Chief Executive Officer of Longbow. “After careful consideration, we believe that our technology and team align seamlessly with Veracode's vision, making this the best choice for Longbow’s future."
“We’re thrilled to welcome Longbow to Veracode and expand our platform capabilities with industry-leading application security posture management for today’s enterprise requirements,” closed Sam King, Chief Executive Officer at Veracode. “The integration of our solutions provides organizations with a holistic application risk management platform that spans code to cloud. Veracode combined with Longbow advances the field of application security and enables customers to secure their increasingly complex application landscape more efficiently.”
Longbow is available immediately. To learn more about the platform, visit the Longbow website. Read the blog for information on the acquisition.
About Veracode
Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Using powerful AI trained on a carefully curated, trusted dataset from experience analyzing trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.
Learn more at www.veracode.com, on the Veracode blog, and on LinkedIn and Twitter.
Copyright © 2024 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401671481/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 15:37:00 CEST | Press release
The new SpeechLive Legal AI Assistant reduces the administrative burden on legal professionals through customizable document drafting powered by speech recognition tuned for legal terminology Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
